Source link : https://www.newshealth.biz/health-news/ada-advises-against-compounded-glp-1s-growth-hormone-therapy-guide-t1d-outcomes-up/
The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and dual GIP/GIP-1 receptor agonists for type 2 diabetes or obesity and instead recommended switching to a different FDA-approved medication if an agent is unavailable. (Diabetes Care) Patients with hypothyroidism who lost more than over 5 lb with a GLP-1 agent […]
Author : News Health
Publish date : 2024-12-03 18:54:05
Copyright for syndicated content belongs to the linked Source.